Allogene CAR-Ts’ Durability Remains A Question, But Strong Data So Far

Pivotal Trial Likely To Include Consolidation Dosing

 
• By Alaric DeArment
  
Generate a summary of this article
Listen to this article
Beta

Complete response rates for ALLO-501 and ALLO-501A look comparable so far to Gilead’s Yescarta, though longer follow-up is needed to judge if durability matches as well.

Digital illustration of Cancer cell in colour background
Allogene announced data for its off-the-shelf CAR-Ts in non-Hodgkin's lymphoma • Source: Shutterstock

Allogene Therapeutics Inc.’s interim Phase I data for its allogeneic chimeric antigen receptor T-cell (CAR-T) therapies, ALLO-501 and ALLO-501A, look increasingly comparable to marketed autologous CAR-Ts in terms of response rates among patients with B-cell non-Hodgkin’s lymphomas, particularly with their added advantage of enabling consolidation treatment. But while those responses look durable so far, a lingering question is whether that durability will continue long enough to approach or match the durable responses seen with their autologous cousins.

South San Francisco, CA-based Allogene announced 19 May data from the ALPHA study of ALLO-501 and the ALPHA2 study of...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from ASCO

TIL The CARs Come Home: How Cell Therapy’s Solid Tumor Future Is Shaping Up

 
• By Alaric DeArment

Iovance’s Amtagvi won FDA accelerated approval in February, and Adaptimmune’s afami-cel may not be far behind, but cell therapies for solid tumors come with some extra challenges.

Anti-TROP2 ADCs Lung Cancer Futures Likely Lie In Earlier-Stage Disease

 
• By Alaric DeArment

The discussant at ASCO’s NSCLC session said the field would need to “manage expectations” as the drugs do not appear to beat chemotherapy in all-comers. 

ASCO 2024 Wrap-Up Podcast

 
• By Alaric DeArment

Scrip reporter Alaric DeArment is joined by the Datamonitor Healthcare oncology analysts to review key highlights from the recent American Society of Clinical Oncology annual meeting.   

China Biotech Podcast: BIOSECURE Act Updates ASCO Highlights

 
• By Brian Yang and Dexter Jie Yan

US-based Citeline writer Sarah Karlin-Smith joins Brian Yang and Dexter Yan in China to discuss the US BIOSECURE Act and the recent BIO meeting in San Diego, while Dexter Yan discusses China-related ASCO highlights, in this mixed Chinese- and English-language episode.

More from Conferences

ESMO 24: NIAGARA – Trial Design Question Hangs Over Imfinzi’s Bladder Cancer Return

 
• By Alexandra Shimmings

AstraZeneca’s NIAGARA trial of perioperative Imfinzi in bladder cancer was positively received at the ESMO meeting but its design did not distinguish the contributions of each treatment portion to the overall effect – something that the US FDA is likely to have a view on.    

ESMO 24: Incyte’s Zynyz Finally Mounts The POD1UM

 
• By Alexandra Shimmings

Persistence has paid off for Incyte’s Zynyz in anal cancer with a Phase III win that should make up for a previous disappointment at the FDA and give a boost to the firm’s pipeline prospects for a post-Jakafi era.    

Sutro Works Toward A Better Ovarian Cancer ADC

 
• By Mandy Jackson

Sutro Biopharma CEO Bill Newell spoke with Scrip about the company’s novel platform, its goal of improving folate receptor alpha-driven ovarian cancer and its business development strategy.